IL17A and arthritic joint disease: Mice that received combined treatment of cromolyn and anti-IL-17A showed minor wight loss and significantly reduced clinical severity of arthritis relative to mice that only received anti-IL-17A treatment, suggesting that mast cell blockade may potentiate the biological therapy (Fig. 6b, c).